ONXOL is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary.ONXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.Prior therapy should have included an anthracycline unless clinically contraindicated.
Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2-4% of patients receiving paclitaxel in clinical trials.
Fatal reactions have occurred in patients despite premedication.
All patients should be pretreated with corticosteroids, diphenhydramine and H2 antagonists.
(See “DOSAGE AND ADMINISTRATION” section.) Patients who experience severe hypersensitivity reactions to ONXOL should not be rechallenged with the drug.Bone marrow suppression (primarily neutropenia) is dose-dependent and is the dose-limiting toxicity.
Neutrophil nadirs occurred at a median of 11 days.
ONXOL should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3 (<1,000 cells/mm3 for patients with KS).
Frequent monitoring of blood counts should be instituted during ONXOL treatment.
Patients should not be re-treated with subsequent cycles of ONXOL until neutrophils recover to a level >1,500 cells/mm3 (>1,000 cells/mm3 for patients with KS) and platelets recover to a level >100,000 cells/mm3.Severe conduction abnormalities have been documented in <1% of patients during ONXOL therapy and in some cases requiring pacemaker placement.
If patients develop significant conduction abnormalities during paclitaxel infusion, appropriate therapy should be administered and continuous cardiac monitoring should be performed during subsequent therapy with ONXOL.Pregnancy: ONXOL can cause fetal harm when administered to a pregnant woman.
Administration of paclitaxel during the period of organogenesis to rabbits at doses of 3 mg/kg/day (about 0.2 the daily maximum recommended human dose on a mg/m2 basis) caused embryo and fetotoxicity, as indicated by intrauterine mortality, increased resorptions and increased fetal deaths.
Maternal toxicity was also observed at this dose.
No teratogenic effects were observed at 1 mg/kg/day (about 1/15 the daily maximum recommended human dose on a mg/m2 basis); teratogenic potential could not be assessed at higher doses due to extensive fetal mortality.
There are no adequate and well controlled studies in pregnant women.
If ONXOL is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.Women of childbearing potential should be advised to avoid becoming pregnant.